STOCK TITAN
  1. Home
  2. Sec-filings
  3. SUPN
  4. [Form 4] SUPERNUS PHARMACEUTICALS, INC. Insider Trading Activity

Supernus (SUPN) director awarded 2,989 RSUs and 4,977 stock options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Hudson Frederick M. reported acquisition or exercise transactions in this Form 4 filing.

SUPERNUS PHARMACEUTICALS, INC. director Frederick M. Hudson reported equity awards consisting of restricted stock units and stock options. He was granted 2,989 restricted stock units and 4,977 director stock options on February 18, 2026, each at a grant price of $0 per unit or option.

Each restricted stock unit represents one share of Supernus common stock and will be settled in common stock when it vests on February 18, 2027. The stock options also vest on February 18, 2027, giving him the right to buy Supernus common stock in the future, subject to the option terms.

Positive

  • None.

Negative

  • None.
Insider Hudson Frederick M.
Role Director
Type Security Shares Price Value
Grant/Award Restricted Stock Unit 2,989 $0.00 --
Grant/Award Director Stock Option (Right to Buy) 4,977 $0.00 --
Holdings After Transaction: Restricted Stock Unit — 2,989 shares (Direct); Director Stock Option (Right to Buy) — 4,977 shares (Direct)
Footnotes (1)
  1. Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. These restricted stock units will be settled in common stock upon vesting, which will occur on February 18, 2027. Each option vests on February 18, 2027.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Hudson Frederick M.
(Last) (First) (Middle)
C/O SUPERNUS PHARMACEUTICALS, INC.,
9715 KEY WEST AVENUE
(Street)
ROCKVILLE MD 20850
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
SUPERNUS PHARMACEUTICALS, INC. [ SUPN ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
02/18/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Unit (1) 02/18/2026 A 2,989 (2) (2) Common Stock 2,989 $0 2,989 D
Director Stock Option (Right to Buy) $50.2 02/18/2026 A 4,977 (3) 02/18/2036 Common Stock 4,977 $0 4,977 D
Explanation of Responses:
1. Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting.
2. These restricted stock units will be settled in common stock upon vesting, which will occur on February 18, 2027.
3. Each option vests on February 18, 2027.
Remarks:
/s/ Timothy C. Dec, as attorney-in-fact 02/20/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did SUPN director Frederick M. Hudson report on this Form 4?

Director Frederick M. Hudson reported two equity award grants: 2,989 restricted stock units and 4,977 director stock options. Both awards were granted on February 18, 2026, at a grant price of $0, and represent non-cash compensation in Supernus equity.

How many restricted stock units did Frederick M. Hudson receive from Supernus (SUPN)?

Frederick M. Hudson received 2,989 restricted stock units from Supernus. Each unit represents the right to receive one share of Supernus common stock when it vests, providing stock-based compensation aligned with future service and company performance.

When do Frederick M. Hudson’s restricted stock units in SUPN vest?

Hudson’s restricted stock units vest on February 18, 2027. At vesting, each of the 2,989 units will be settled in one share of Supernus common stock, converting the award into actual share ownership, subject to any applicable plan terms.

What stock options were granted to Frederick M. Hudson by Supernus (SUPN)?

Hudson was granted 4,977 director stock options, described as a right to buy Supernus common stock. These options were awarded on February 18, 2026, at a grant price of $0 and vest in full on February 18, 2027, per the disclosure.

Is the Form 4 for SUPN a buy or sell transaction for Frederick M. Hudson?

The Form 4 reports acquisitions through equity awards, not open-market buys or sales. The transactions are coded as grants of restricted stock units and stock options, providing additional potential ownership without immediate cash purchases or stock disposals.

How many Supernus (SUPN) derivative securities does Frederick M. Hudson hold after these grants?

After the grants, Hudson holds 2,989 restricted stock units and 4,977 director stock options as reported totals. These amounts reflect his derivative equity awards following the February 18, 2026 transactions described in the Form 4 filing.